What is Novadiscovery?
Founded in 2010 and headquartered in Lyon, France, Novadiscovery operates at the intersection of health technology and computational science. The company specializes in in silico clinical trials, a sophisticated methodology that utilizes computer simulation to predict drug efficacy and safety profiles before human testing begins. By leveraging advanced mathematical modeling, Novadiscovery enables pharmaceutical developers to optimize their R&D pipelines, significantly reducing the risk of late-stage clinical failure and enhancing overall productivity. This approach is increasingly vital as the industry seeks to maximize patient outcomes while navigating the rising costs and complexities of modern drug development.
How much funding has Novadiscovery raised?
Novadiscovery has raised a total of $9.1M across 1 funding round:
Series A
$9.1M
Series A (2021): $9.1M with participation from Sanofi and Debiopharm
Key Investors in Novadiscovery
Sanofi
Sanofi is a global biopharmaceutical leader focused on discovering and delivering innovative medicines and vaccines across diverse therapeutic areas including immunology and oncology.
Debiopharm
Debiopharm is a Swiss-based biopharmaceutical company that invests in and develops innovative therapies and digital health solutions to address high unmet medical needs.
What's next for Novadiscovery?
Following this major enterprise-level funding, Novadiscovery is well-positioned to scale its operations and expand the reach of its simulation platform. The strategic backing from industry leaders suggests a clear trajectory toward broader adoption of in silico methodologies within the global biopharmaceutical sector. Moving forward, the company is expected to focus on deepening its clinical trial simulation capabilities, potentially integrating more complex biological data sets to further refine predictive accuracy. As the regulatory environment continues to evolve, Novadiscovery's ability to provide data-driven insights will likely serve as a cornerstone for future drug development strategies, positioning the firm as an essential partner for global pharmaceutical entities aiming to accelerate time-to-market for life-saving therapies.
See full Novadiscovery company page
